Sanofi provides pipeline update at JPMorgan
Sanofi (Euronext:SAN; NYSE:SNY) said that it has 17 new molecular entities in its pipeline that are in Phase III trials or under regulatory review, with regulatory milestones for eight products expected in the next six months. The details came in an R&D pipeline update on Tuesday at the 31st Annual JPMorgan Healthcare Conference. The pharma said it discontinued development of cancer compound ombrabulin after data from a Phase III trial for advanced soft tissue sarcoma (STS) showed that ombrabulin plus cisplatin did not "demonstrate sufficient clinical benefit to support regulatory submissions" despite meeting the primary endpoint of improving progression-free survival (PFS) vs. placebo. Sanofi also said that it terminated early a Phase II trial evaluating ombrabulin in patients with ovarian cancer based on an interim analysis. Sanofi has exclusive, worldwide rights to the vascular disrupting agent from Ajinomoto Co. Inc. (Tokyo:2802). ...